ArticleCurrent cancer drug targets2025

Efficacy and Safety of PD-1/L1 Inhibitors Combined with Anlotinib versus PD-1/L1 Inhibitors Combined with Bevacizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients: A Comparative Cohort Study.

Xiaobing Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.